Shots:

• Inflazome to receive $450.31M as up front and is eligible to receive additional contingent payments based on the achievement of certain predetermined milestones
• The acquisition allows the Roche to get full rights to Inflazome’s portfolio consisting of pre/ clinical orally available small molecule NLRP3 inhibitors
• Roche will further advance the NLRP3 inhibitors across a wide variety of indications targeting the unmet medical needs across a wide variety of inflammatory diseases

­ Ref: PRNewswire | Image: Roche